Search Results

There are 3330 results for: content related to: Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors

  1. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma

    Head & Neck

    Volume 34, Issue 9, September 2012, Pages: 1269–1276, Jonah D. Klein, Apostolos Christopoulos, Sun M. Ahn, William E. Gooding, Jennifer R. Grandis and Seungwon Kim

    Article first published online : 6 FEB 2012, DOI: 10.1002/hed.21917

  2. You have full text access to this OnlineOpen article
    A novel therapeutic combination for neuroblastoma

    Cancer

    Volume 116, Issue 10, 15 May 2010, Pages: 2465–2475, Peter E. Zage, Lizhi Zeng, Shana Palla, Wendy Fang, Monique B. Nilsson, John V. Heymach and Patrick A. Zweidler-McKay

    Article first published online : 11 MAR 2010, DOI: 10.1002/cncr.25017

  3. You have free access to this content
    Targeted therapy: An evolving world of lung cancer

    Respirology

    Volume 16, Issue 1, January 2011, Pages: 13–21, Kwok-Chi LAM and Tony S. MOK

    Article first published online : 16 AUG 2010, DOI: 10.1111/j.1440-1843.2010.01821.x

  4. Tyrosine Kinase Inhibitors

    Targeting Protein Kinases for Cancer Therapy

    David J. Matthews, Mary E. Gerritsen, Pages: 435–525, 2010

    Published Online : 11 MAR 2010, DOI: 10.1002/9780470555293.ch8

  5. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

    Journal of Cellular Physiology

    Volume 216, Issue 3, September 2008, Pages: 698–707, Tina Cascone, Maria Pia Morelli, Floriana Morgillo, Woo-Young Kim, Gabriella Rodolico, Stefano Pepe, Liberato Berrino, Ho-Young Lee, John V. Heymach and Fortunato Ciardiello

    Article first published online : 31 MAR 2008, DOI: 10.1002/jcp.21444

  6. You have full text access to this OnlineOpen article
    Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials

    British Journal of Clinical Pharmacology

    Volume 75, Issue 4, April 2013, Pages: 919–930, Wei-Xiang Qi, Zan Shen, Feng Lin, Yuan-jue Sun, Da-liu Min, Li-Na Tang, Ai-Na He and Yang Yao

    Article first published online : 15 MAR 2013, DOI: 10.1111/j.1365-2125.2012.04417.x

  7. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner

    BJU International

    Volume 103, Issue 12, June 2009, Pages: 1729–1737, Thomas W. Flaig, Lih-Jen Su, Caroline McCoach, Yuan Li, David Raben, Marileila Varella-Garcia and Lynne T. Bemis

    Article first published online : 10 FEB 2009, DOI: 10.1111/j.1464-410X.2009.08367.x

  8. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model

    Head & Neck

    Volume 33, Issue 3, March 2011, Pages: 349–358, Daisuke Sano, David R. Fooshee, Mei Zhao, Genevieve A. Andrews, Mitchell J. Frederick, Chad Galer, Zvonimir L. Milas, Phuong Khanh H. Morrow and Jeffrey N. Myers

    Article first published online : 13 JUL 2010, DOI: 10.1002/hed.21455

  9. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250

    BJU International

    Volume 107, Issue 1, January 2011, Pages: 118–125, Jeannette C. Oosterwijk-Wakka, Gürsah Kats-Ugurlu, William P.J. Leenders, Lambertus A.L.M. Kiemeney, Lloyd J. Old, Peter F.A. Mulders and Egbert Oosterwijk

    Article first published online : 16 MAR 2010, DOI: 10.1111/j.1464-410X.2010.09314.x

  10. You have free access to this content
    Understanding, recognizing, and managing toxicities of targeted anticancer therapies

    CA: A Cancer Journal for Clinicians

    Volume 63, Issue 4, July/August 2013, Pages: 249–279, Grace K. Dy and Alex A. Adjei

    Article first published online : 28 MAY 2013, DOI: 10.3322/caac.21184

  11. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

    International Journal of Gynecological Cancer

    Volume 18, Issue 5, September/October 2008, Pages: 879–890, M.J. PALAYEKAR and T.J. HERZOG

    Article first published online : 5 DEC 2007, DOI: 10.1111/j.1525-1438.2007.01144.x

  12. Angiokinase Inhibitors

    Targeting Protein Kinases for Cancer Therapy

    David J. Matthews, Mary E. Gerritsen, Pages: 527–565, 2010

    Published Online : 11 MAR 2010, DOI: 10.1002/9780470555293.ch9

  13. You have free access to this content
    Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma

    British Journal of Pharmacology

    Volume 166, Issue 2, May 2012, Pages: 532–553, Roberto E Favoni, Antonio Daga, Paolo Malatesta and Tullio Florio

    Article first published online : 13 APR 2012, DOI: 10.1111/j.1476-5381.2012.01873.x

  14. Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis

    International Journal of Cancer

    Volume 132, Issue 12, 15 June 2013, Pages: 2967–2974, Wei-Xiang Qi, Da-Liu Min, Zan Shen, Yuan-Jue Sun, Feng Lin, Li-Na Tang, Ai-Na He and Yang Yao

    Article first published online : 27 DEC 2012, DOI: 10.1002/ijc.27979

  15. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models

    The Journal of Pathology

    Volume 223, Issue 5, April 2011, Pages: 626–634, Anna C Navis, Bob C Hamans, An Claes, Arend Heerschap, Judith WM Jeuken, Pieter Wesseling and William PJ Leenders

    Article first published online : 21 FEB 2011, DOI: 10.1002/path.2836

  16. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors

    British Journal of Clinical Pharmacology

    Volume 76, Issue 3, September 2013, Pages: 396–411, Rashmi R. Shah, Samantha A. Roberts and Devron R. Shah

    Article first published online : 20 AUG 2013, DOI: 10.1111/bcp.12085

  17. You have open access to this content
    It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor–vascular endothelial growth factor receptor pathway in patients with solid malignancies

    Cancer Science

    Volume 101, Issue 1, January 2010, Pages: 7–15, Ingrid A. Boere, Paul Hamberg and Stefan Sleijfer

    Article first published online : 18 SEP 2009, DOI: 10.1111/j.1349-7006.2009.01369.x

  18. Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies

    Fundamental & Clinical Pharmacology

    Zhi-Xin Wang, Jiazhi Sun, Caitlin E. Howell, Qing-Yu Zhou, Zhi-Xu He, Tianxin Yang, Helen Chew, Wei Duan, Zhi-Wei Zhou, Jagat R. Kanwar and Shu-Feng Zhou

    Article first published online : 21 MAR 2014, DOI: 10.1111/fcp.12069

  19. Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines

    Veterinary and Comparative Oncology

    Volume 9, Issue 3, September 2011, Pages: 196–206, K. C. Kennedy, B. A. Qurollo, B. J. Rose and D. H. Thamm

    Article first published online : 22 NOV 2010, DOI: 10.1111/j.1476-5829.2010.00248.x

  20. You have full text access to this OnlineOpen article
    Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways

    International Journal of Cancer

    Volume 127, Issue 5, 1 September 2010, Pages: 1197–1208, Orestis Lyros, Annett Mueller, Florian Heidel, Carl C. Schimanski, Ines Gockel, Peter R. Galle, Hauke Lang and Markus Moehler

    Article first published online : 28 DEC 2009, DOI: 10.1002/ijc.25137